Share on LinkedInShare on LinkedIn

ARTICLE · 02 JULY 2018

Update On Biosimilars

Further to our update in December 2017, here, below is a mid-year update on biosimilar approvals, litigation and other news.

CanadaFood, Drugs, Healthcare, Life Sciences

Further to our update in December 2017, here, below is a mid-year update on biosimilar approvals, litigation and other news.

Approvals of biosimilars:

In the first half of 2018, Health Canada approved three biosimilars based on three different reference products, bringing the total number of biosimilar approvals to 11, based on 8 reference products.

Biosimilar Manufacturer and date of approval Review time (from filing to approval) Medicinal ingredient
HADLIMA, HADLIMA PUSHTOUCH Samsung Bioepis, May 8, 2018 Not available adalimumab
LAPELGA Apotex, April 5, 2018 349 days pegfilgrastim
MVASI Amgen, April 30, 2018 487 days bevacizumab

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from